Century Fire Protection Expands Geographic Footprint to Western U.S.

3 minutes ago
GlobeNewswire

Acquires Utah-Based TST Fire Protection and Alliance Fire & SafetyTORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- FirstService Corporation (TSX and…

Base Carbon Reports First-Quarter 2025 Operating and Financial Results and Upcoming Investor Update Call

3 minutes ago

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned…

Newton Golf Company Reports First Quarter 2025 Financial Results

3 minutes ago

Revenue Surges 246% Year-Over-Year as Newton Motion Shaft Adoption Accelerates Across Major ToursCAMARILLO, Calif., May 15, 2025 (GLOBE NEWSWIRE) --…

ZenaTech Reports Nearly Double Revenue Year-Over-Year for the First Quarter of 2025

3 minutes ago

VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology…

Skyharbour and JV Partner Orano to Commence Extensive Summer 2025 Drilling Program at Preston Uranium Project

3 minutes ago

Vancouver, BC, May 15, 2025 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”), is…

Digi Power X Reports 65% Increase in Q1 2025 Revenue Over Prior Quarter With no Long-Term Debt

3 minutes ago

MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX /…

Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

3 minutes ago

- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene…

FitLife Brands Announces First Quarter 2025 Results

3 minutes ago

OMAHA, NE, May 15, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of…

Avicanna Reports Q1 2025 Results and First Profitable Quarter

3 minutes ago

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a…

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

3 minutes ago

Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic…

This website uses cookies.